JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms (Q37810100)

23 August 2017

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms (English)

1 reference

23 August 2017

0 references

Stephen T Oh

1

1 reference

PubMed ID

21082983

23 August 2017

Jason Gotlib

series ordinal

2

1 reference

23 August 2017

1 June 2010

1 reference

Expert Review of Hematology

23 August 2017

1 reference

23 August 2017

3

1 reference

23 August 2017

3

1 reference

23 August 2017

323-337

1 reference

Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989.

23 August 2017

1 reference

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

21 January 2018

1 reference

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

Polycythemia vera: stem-cell and probable clonal origin of the disease

21 January 2018

1 reference

Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3.

21 January 2018

1 reference

Oncogenes in myeloproliferative disorders

21 January 2018

1 reference

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

21 January 2018

1 reference

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

Jak2: normal function and role in hematopoietic disorders

21 January 2018

1 reference

Signaling through the JAK/STAT pathway, recent advances and future challenges

21 January 2018

1 reference

JAK/STAT signal transduction: regulators and implication in hematological malignancies

21 January 2018

1 reference

STAT3 is constitutively active in some patients with Polycythemia rubra vera

21 January 2018

1 reference

Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.

21 January 2018

1 reference

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

21 January 2018

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

21 January 2018

1 reference

JAK and MPL mutations in myeloid malignancies

21 January 2018

1 reference

Characterization of murine JAK2V617F-positive myeloproliferative disease

21 January 2018

1 reference

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

21 January 2018

1 reference

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

21 January 2018

1 reference

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

21 January 2018

1 reference

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

21 January 2018

1 reference

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

21 January 2018

1 reference

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

21 January 2018

1 reference

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 January 2018

1 reference

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

21 January 2018

1 reference

Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis.

21 January 2018

1 reference

Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera.

21 January 2018

1 reference

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

21 January 2018

1 reference

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

21 January 2018

1 reference

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms

21 January 2018

1 reference

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.

21 January 2018

1 reference

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

21 January 2018

1 reference

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

21 January 2018

1 reference

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

21 January 2018

1 reference

In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.

21 January 2018

1 reference

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

21 January 2018

1 reference

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias

21 January 2018

1 reference

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

21 January 2018

1 reference

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

21 January 2018

1 reference

Acquired mutations in TET2 are common in myelodysplastic syndromes

21 January 2018

1 reference

Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.

21 January 2018

1 reference

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

21 January 2018

1 reference

TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23).

21 January 2018

1 reference

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

21 January 2018

1 reference

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

SOCS regulation of the JAK/STAT signalling pathway

21 January 2018

1 reference

Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

21 January 2018

1 reference

A new protein containing an SH2 domain that inhibits JAK kinases

21 January 2018

1 reference

Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain

21 January 2018

1 reference

Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation

21 January 2018

1 reference

Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.

21 January 2018

1 reference

A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor

21 January 2018

1 reference

Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders

21 January 2018

1 reference

Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.

21 January 2018

1 reference

Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases

21 January 2018

1 reference

SOCS2: inhibitor of JAK2V617F-mediated signal transduction

21 January 2018

1 reference

Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation

21 January 2018

1 reference

Control of B cell production by the adaptor protein lnk. Definition Of a conserved family of signal-modulating proteins

21 January 2018

1 reference

Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk

21 January 2018

1 reference

Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice

21 January 2018

1 reference

Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis

21 January 2018

1 reference

Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK.

21 January 2018

1 reference

Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways

21 January 2018

1 reference

Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders

21 January 2018

1 reference

Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells

21 January 2018

1 reference

The Cbl interactome and its functions

21 January 2018

1 reference

v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas

21 January 2018

1 reference

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia

21 January 2018

1 reference

Flt3-dependent transformation by inactivating c-Cbl mutations in AML

21 January 2018

1 reference

250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies

21 January 2018

1 reference

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

21 January 2018

1 reference

Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

21 January 2018

1 reference

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

21 January 2018

1 reference

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia

21 January 2018

1 reference

Expression of Bcl-x in erythroid precursors from patients with polycythemia vera

21 January 2018

1 reference

JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

21 January 2018

1 reference

DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH.

21 January 2018

1 reference

Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders

21 January 2018

1 reference

Taxing sugar-sweetened beverages

21 January 2018

1 reference

Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells

21 January 2018

1 reference

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

21 January 2018

1 reference

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

21 January 2018

1 reference

JAK2 Mutations are present in all cases of polycythemia vera

21 January 2018

1 reference

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.10.28

1 reference

23 August 2017

1 reference

PubMed ID

21082983